Beactica
develops small molecule allosteric modulators for the treatment of glioblastoma... Read moreBeactica
develops small molecule allosteric modulators for the treatment of glioblastoma... Read more
News
Feb 17, 2026
Pulse2.0
Beactica: Beactica Therapeutics Secures 2.5 Million EIC Grant To Advance Orphan Drug BEA-17 Toward Clinical Trials
Oct 07, 2025
FinanzNachrichten
Beactica: Beactica Therapeutics AB: Beactica conducts first advisory meeting with the Swedish Medical Products Agency regarding the development of BEA-17
Feb 14, 2024
FinanzNachrichten
Beactica: Beactica Therapeutics AB: Beactica Therapeutics' TEAD programme selected for late-breaking research presentation at the AACR Annual Meeting 2024
Sep 27, 2023
Pharmabiz
Beactica: Beactica Therapeutics collaborates with NCATS to focus on translation of novel proteolysistargeting degraders of TEAD to treat cancer
Sep 26, 2023
BioSpace
Beactica: Beactica Therapeutics announces collaboration with the National Center for Advancing Translational Sciences
Sep 12, 2023
FinanzNachrichten
Beactica: Beactica Therapeutics AB: Beactica Therapeutics strengthens its preclinical development team
May 16, 2023
FinanzNachrichten
Beactica: Beactica Therapeutics AB: Beactica Therapeutics to present breakthrough in YAP-TEAD programme at the Hippo Pathway Drug Development Summit 2023
Apr 11, 2023
FinanzNachrichten
Beactica: Beactica Therapeutics AB: Beactica Therapeutics to present update on LSD1 programme at the AACR Annual Meeting 2023
Apr 04, 2023
BioSpace
Beactica: Beactica Therapeutics and Oscotec mutually agree to conclude oncology collaboration
Feb 02, 2023
Pharmabiz
Beactica: US FDA grants orphan drug designation to Beactica Therapeutics' BEA17 for glioblastoma treatment
Beactica Competitors
1
2
3
4
5
6
7
8
9
10